Navigation Links
Regeneron Named World's #1 Biopharmaceutical Employer in Science Magazine Annual Survey
Date:9/21/2012

TARRYTOWN, N.Y., Sept. 21, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that Science magazine has ranked Regeneron as the #1 employer in the global biopharmaceutical industry in the journal's annual Top Employers Survey.

"This recognition by Science as the most respected company to work for in the biopharmaceutical industry is very satisfying for all of us at Regeneron," said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron Pharmaceuticals and George D. Yancopoulos, M.D., Ph.D., Chief Scientific Officer and President, Regeneron Laboratories.  "Since we opened our first lab in 1989, we have believed that innovative science could be harnessed to deliver important new medicines for serious conditions.  As we have grown from a handful of people to nearly 1,900 employees today, we have worked hard to maintain a culture that values rigorous science, creative thinking, and collegiality.  We are fortunate to have such talented employees who are dedicated to discovering and developing new treatments for patients in need."

This is the first year that Regeneron has captured the #1 position and the first time a New York based company has topped the survey.  Last year Regeneron was ranked #2.

The 2012 survey sought to identify the companies with the best reputations as employers, based on 4,276 survey responses from readers of Science and other survey invitees.  Survey participants came from North America (78%), Europe (14%), and Asia/Pacific Rim (5%); 93% worked in private industry.  Details of the rankings and survey results can be found in the September 21 online edition of Science and will be featured in the October 19, 2012 print issue.

On Monday, September 24, New York State Lt. Governor Robert Duffy and U.S. Congresswoman Nita Lowey and other public officials are scheduled to participate in an event with Regeneron's Tarrytown employees that will recognize this important achievement.

Separately, Regeneron announced another step to reinforce its commitment to science by launching a new Post-Doctoral Training Program that is accepting applications for its 2013 class.  The three-year multi-faceted program will integrate cutting edge science with didactic training, discussion groups, and focused mentoring.

About Regeneron Pharmaceuticals, Inc.  
Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets three products in the United States, EYLEA® (aflibercept) Injection, ZALTRAP® (ziv-aflibercept) Injection for Intravenous Infusion, and ARCALYST® (rilonacept) Injection for Subcutaneous Use; ZALTRAP is co-commercialized with Sanofi.  Regeneron has filed a regulatory application with the U.S. Food and Drug Administration (FDA) for a second indication for EYLEA.  Phase 3 studies are in progress with EYLEA in two additional indications and with product candidates sarilumab and REGN727.  Regeneron has active research and development programs in many disease areas, including ophthalmology, inflammation, cancer, and hypercholesterolemia.  Additional information and recent news releases are available on the Regeneron web site at www.regeneron.com.

Contact Information:   
Peter Dworkin   
Corporate Communications  
914.847.7640  
peter.dworkin@regeneron.com

Manisha Narasimhan, Ph.D.  
Investor Relations    
914.847.5126    
manisha.narasimhan@regeneron.com


'/>"/>
SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Regeneron Announces September 2012 Investor Conference Presentations
2. Regeneron to Report Second Quarter 2012 Financial and Operating Results and Host Conference Call and Webcast on July 25, 2012
3. Regeneron Announces June 2012 Investor Conference Presentations
4. Regeneron Provides Update On FDA Advisory Committee Discussion of ARCALYST® (rilonacept) Injection
5. Regeneron and Bayer Announce Co-Promotion Agreement With Santen For EYLEA® (aflibercept) Injection in Japan
6. Mersana Therapeutics Named a "Fierce 15" Biotech Company for 2012
7. Donor Alliance Named Colorados Top Healthcare Company
8. Millennium Laboratories Angela Huskey Named Industry Pain Educator of the Year by American Society of Pain Educators
9. Impact Advisors Named to Inc. 5000 List of Nations Fastest-Growing Companies
10. Ingenuity Systems Named 2013 World Economic Forum Technology Pioneer
11. Saddleback Memorial Named First Robotic Training Epicenter for Gynecologic Surgery in Orange County
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2019)... Fla. (PRWEB) , ... August 19, 2019 , ... ... will be hosting their 2nd Annual National Sports Summit, August 25-26 at ... former athletes, and clinical leaders from all major professional sports programs to discuss ...
(Date:8/19/2019)... ... August 19, 2019 , ... Sheba Medical ... findings of research validating the clinical impact of MedAware’s machine learning-enabled patient safety ... 2019 in the Journal of American Medical Informatics Association (JAMIA) in ...
(Date:8/19/2019)... ... August 19, 2019 , ... ... Khoury, M.D., will join its Richardson, Texas location, starting Monday, Sep. 2nd. , ... Anesthesiology with a subspecialty board certification in pain management. , Dr. Khoury attended ...
Breaking Medicine Technology:
(Date:8/15/2019)... ... August 15, 2019 , ... With many students either starting college for the first ... particular demographic. According to the CDC , “there are about 20 million new cases ... people between the ages of 15 and 24. Young people are at greater risk of ...
(Date:8/15/2019)... BRADLEY, Ill. (PRWEB) , ... August 15, 2019 , ... ... by the National Center for Assisted Living (NCAL). , This award is part of ... of the assisted living profession. , “The common element among this year’s recipients is ...
(Date:8/14/2019)... ... August 14, 2019 , ... Inc. magazine today revealed that RKC ... 5000 list, the most prestigious ranking of the nation’s fastest-growing private companies. With 200% ... and #153 in the Health sector. The list represents a unique look at the ...
(Date:8/14/2019)... SAN DIEGO, Calif. (PRWEB) , ... August 15, ... ... opening of its first international clinic in Tijuana Mexico. R3 Stem Cell International ... who are appropriately licensed in Mexico. , A full procedure costs only $2950, ...
(Date:8/14/2019)... ... August 13, 2019 , ... Dr. Rachel Reyes-Bergano, a ... , The Haute Beauty Network, well known for its exclusive and luxurious lifestyle ... medicine expert and our newest addition to the Haute Beauty members-only network. , ...
Breaking Medicine News(10 mins):